Brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to post earnings per share of $0.62 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Endo International’s earnings. The highest EPS estimate is $0.70 and the lowest is $0.55. Endo International posted earnings per share of $1.77 during the same quarter last year, which indicates a negative year-over-year growth rate of 65%. The company is scheduled to report its next earnings report on Tuesday, February 27th.
On average, analysts expect that Endo International will report full-year earnings of $3.67 per share for the current financial year, with EPS estimates ranging from $3.63 to $3.77. For the next fiscal year, analysts anticipate that the business will report earnings of $3.01 per share, with EPS estimates ranging from $2.55 to $3.80. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. The business had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.01 earnings per share.
Several equities research analysts have weighed in on the company. Vetr cut Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 target price for the company. in a research note on Monday. Guggenheim started coverage on Endo International in a research note on Tuesday, December 12th. They issued a “neutral” rating and a $8.50 price target for the company. ValuEngine upgraded Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BidaskClub upgraded Endo International from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, Cantor Fitzgerald dropped their price target on Endo International from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have assigned a buy rating to the company’s stock. Endo International presently has a consensus rating of “Hold” and an average target price of $11.34.
Several institutional investors and hedge funds have recently modified their holdings of the company. Gamco Investors INC. ET AL lifted its position in Endo International by 5.6% in the 2nd quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company’s stock valued at $700,000 after acquiring an additional 3,300 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Endo International by 20.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 325,860 shares of the company’s stock valued at $3,640,000 after acquiring an additional 56,407 shares in the last quarter. Sivik Global Healthcare LLC bought a new position in Endo International in the 2nd quarter valued at about $2,793,000. Columbia Partners L L C Investment Management bought a new position in Endo International in the 2nd quarter valued at about $1,257,000. Finally, Diamond Hill Capital Management Inc. lifted its position in Endo International by 46.8% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after acquiring an additional 228,426 shares in the last quarter. Institutional investors own 93.06% of the company’s stock.
Shares of Endo International (ENDP) traded down $0.12 during trading hours on Friday, reaching $8.16. The company had a trading volume of 3,441,500 shares, compared to its average volume of 7,053,518. The firm has a market capitalization of $1,820.00, a P/E ratio of 1.71, a P/E/G ratio of 2.26 and a beta of 0.59. Endo International has a 1-year low of $5.77 and a 1-year high of $17.99. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78.
TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/12/analysts-expect-endo-international-plc-endp-to-announce-0-62-earnings-per-share.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Get a free copy of the Zacks research report on Endo International (ENDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.